Trials / Recruiting
RecruitingNCT07050056
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC: A Single Arm, Phase II Clinical Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Northern Jiangsu People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to explore the efficacy and safety of radiotherapy combined with immunotherapy in the neoadjuvant treatment of resectable NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | 200mg, iv, Q3W, 3-4 cycle |
| RADIATION | 3D-CRT/IMRT | 40Gy in 20 fractions |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
- First posted
- 2025-07-03
- Last updated
- 2026-01-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07050056. Inclusion in this directory is not an endorsement.